Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Participants and to Evaluate the Efficacy of Repeat Subcutaneous Doses in Participants With Osteoarthritis of the Knee

Next Previous
Trial Profile

A Two-part Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Participants and to Evaluate the Efficacy of Repeat Subcutaneous Doses in Participants With Osteoarthritis of the Knee

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK-3858279 (Primary) ; GSK-3858279 (Primary)
  • Indications Musculoskeletal pain
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 15 Nov 2023 Results (n=48 from Part B) assessing efficacy, safety, pharmacokinetic of repeated dosing of GSK3858279 in patients with knee osteoarthritis and immunogenicity presented at the ACR Convergence 2023
  • 03 Jun 2023 Results assessing the efficacy, safety, pharmacokinetic and immunogenicity (n=48; Part B) of Gsk3858279 in patients with knee osteoarthritis, presented at the 24th Annual Congress of the European League Against Rheumatism.
  • 19 Oct 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top